Coherus Oncology, Inc. (CHRS) Form 8-K — May 11, 2026
Coherus Oncology, Inc. reported Q1 2026 financial results, with LOQTORZI net revenue of $11.8 million, a 61% increase over $7.3 million in Q1 2025. This growth is driven by volume increases and new patient starts, despite a 5% decrease from Q4 2025 due to severe weather and normal seasonality. The company also announced that patient accrual is complete for the 1L HCC Phase 2 randomized clinical trial for casdozokitug, with initial data expected in mid-2026.
Key figures
- Revenue
- 12310
- Total Debt
- 37147
- Revenue Yoy
- 61
- Cash Position
- 167000
- LOQTORZI net product revenue
- 11800
- LOQTORZI revenue increase vs 2025
- 4500
Price after filing
1 day: -12.3%7 days: -23.6%30 days: -27.2%
Close on the filing date to close N calendar days later (from $1.95). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.